Atopic Dermatitis (AD)NCT07194421
In-Use Tolerance & Efficacy Study Under Dermatological Control of Sunscreen in Adults With Atopic Dermatitis Skin
An observational study of Atopic Dermatitis (AD) and SCORAD Index(15-25), run by Pierre Fabre Dermo Cosmetique at 1 site in Mauritius.
Trial summary
This study evaluates a broad-spectrum SPF50+ sunscreen on 42 adults with Atopic Dermatitis, measuring skin tolerance and barrier function. The study includes several visits as follow : Visit 1: Inclusion (Day 1) Visit 2: Intermediate Visit (Day 8) Visit 3: End of Study (Day 22) Read more about this study
- Who is it for?
- Ages 18 to 45 years
- Conditions the study is for
- Atopic Dermatitis (AD), SCORAD Index(15-25)
- What is being tested?
- Sunscreen RV4620A RP2552
- How many people
- 42 participants
- Where
- 1 siteMauritius
- Study dates
- 10 Oct 2023to 9 Feb 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- No healthy volunteers
- Adult
Study population: Subjects will be recruited from the investigation centre's panel. They will be selected on the basis of inclusion and non inclusion criteria specific to the study and on their ability to comply with the constraints required by the protocol. They will be definitely included in the study after a specific interview and a clinical examination.
Who may be able to join
- Phototype: from I to VI.
- Sun Exposure: Adults anticipating at least 6 exposures of 2 hours each during the study.
- Swimming Sessions: Subjects planning at least 4 swimming sessions, with a minimum of 50% intending to swim twice in the sea and twice in a pool.
- Sensitive Skin: At least 50% of subjects report having sensitive skin.
- Health Insurance: Must be registered with health social security or health insurance.
- Informed Consent: Must have signed the written Informed Consent form (ICF) for study participation.
Show all 21Show fewer
- Personal Information: Must certify the accuracy of personal information provided to the Investigator.
- Health Status: Considered a "healthy subject" by the Investigator (excluding SCORAD considerations).
- Women of Childbearing Potential: Must agree to use an effective contraceptive method throughout the study and for at least 1 month prior to the inclusion visit.
- Criteria Related to Skin Condition:
- Atopic Dermatitis: Subject must present atopic dermatitis according to the U.K Working Party's Diagnostic Criteria for Atopic Dermatitis, with mild atopic dermatitis indicated by a SCORAD score of 15 to 25 (inclusive), determined by a dermatologist.
- Reactivity: Must be reactive to external irritative factors such as chlorine, sand, salt, and sweat.
- Non-Inclusion Criteria:
- Criteria Related to Population:
- Subjects who have participated in another clinical trial within the week before the inclusion visit, or for a longer period if deemed necessary by the Investigator.
- Subjects currently participating or planning to participate in another clinical trial during the study, either in the same or a different investigation center.
- Criteria Related to Subject's Health:
- Subjects experiencing a flare of atopic dermatitis.
- Pregnant or breastfeeding women (for women of childbearing potential).
- Subjects with dermatological conditions that may interfere with study data or are considered hazardous by the Investigator (e.g., pityriasis versicolor, severe pigmentation disorders such as vitiligo, melasma, multiple lentigines, numerous or large congenital nevi).
- Subjects with a personal medical history that may interfere with study data or is incompatible with study requirements (except if required by the Sponsor, e.g., atopic dermatitis).
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
About this study
This study evaluates a broad-spectrum SPF50+ sunscreen on 42 adults with Atopic Dermatitis, measuring skin tolerance and barrier function.
The study includes several visits as follow :
- Visit 1: Inclusion (Day 1)
- Visit 2: Intermediate Visit (Day 8)
- Visit 3: End of Study (Day 22)
- Conditions
- Atopic Dermatitis (AD), SCORAD Index(15-25)
- Being tested
- Sunscreen RV4620A RP2552
- Medical subject headings
- Dermatitis, Atopic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sunscreen RV4620A RP2552Other
Dermo-cosmetic product, Broadspectrum Sunscreen RV4620A RP2552, very high protection product Instructions for product use given to the subjects: Apply before and during sun exposure, at least twice daily. During sun exposure, applications must be renewed as often as necessary, in particular after swimming, perspiring, towelling, in order to ensure a good protection. On days of bad weather, apply the product in the morning and at the beginning of the afternoon.
| Study group | Role | What they receive |
|---|---|---|
| Test group | Adult intended to use Sunscreen RV4620A RP2552 product Receives: Other: Sunscreen RV4620A RP2552 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Global tolerance assessment by the investigator
Global tolerance of the product is assessed on the "tolerance population" which includes all the subjects who applied investigational product at least once.
This assessment allows for attribution of one of the 5 levels : excellent, very good, good, moderate, bad.
Measured: At the end of the study, after Last Patient Out, (after Day 22)
Secondary outcomes (5)
Evaluation Cosmetic Acceptability of the Sunscreen RV4620A - RP2552
The subjects answer a 10-questions questionnaire about user satisfaction, texture, and overall experience with the product, providing insights into its appeal and usability.
Measured: Visit 3 (Day 22)
Evaluation of Irritative Factors with Sunscreen RV4620A - RP2552
The subjects answer a questionnaire regarding the irritative factors
Measured: Visit 1 (Day 1, before investigational product application) and Visit 3 (Day 22)
Evaluation of Transepidermal Water Loss with Sunscreen RV4620A - RP2552
Trans Epidermal Water Loss measurements are done with a Tewameter TM 300® by a trained technician in a room with controlled temperature and hygrometry. This measurement aims to assess the effect of the investigational product on transepidermal water loss to determine the product's impact on the skin's barrier function.
Measured: Visit 1 (Day 1, before investigational product application) and Visit 3 (Day 22)
Assessment of Skin pH with Sunscreen RV4620A - RP2552
Measurement of the skin pH is done using the COURAGE \& KHAZAKA PH 900 PC Skin pH meter fitted with an Ingold electrode. The goal is to determine the product's respect of skin surface pH.
Measured: Visit 1 (Day 1, before investigational product application) and Visit 3 (Day 22)
Assessment of the Lipidic Index Evolution with Sunscreen RV4620A - RP2552
The quantity of sebum excreted to the skin surface is quantitatively evaluated with a Sebumeter SM 815 (Courage \& Khazaka). The goal is to determine the product's respect of skin's barrier function and seboregulating effect
Measured: Visit 1 (Day 1, before investigational product application) and Visit 3 (Day 22)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Sep 2025
- Study start10 Oct 2023
- Primary completion9 Feb 2024
- Study completion9 Feb 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atopic Dermatitis (AD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 42 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pierre Fabre Dermo Cosmetique
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07194421
- Sponsor's protocol ID
- RV4620A20230439
- Status last verified
- Sep 2025
- First submitted
- 11 Sep 2025
- Last updated
- 26 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- In-Use Tolerance & Efficacy Study Under Dermatological Control of Sunscreen in Adults With Atopic Dermatitis Skin
- ClinicalTrials.gov ID
- NCT07194421
- Acronym / sponsor ID
- RV4620A20230439
- Conditions
- Atopic Dermatitis (AD), SCORAD Index(15-25)
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 42 participants (actual)
- Lead sponsor
- Pierre Fabre Dermo CosmetiqueIndustry (pharma, biotech, devices)
- Study start
- 10 Oct 2023 (actual)
- Primary completion
- 9 Feb 2024 (actual)
- Study completion
- 9 Feb 2024 (actual)
- First posted
- 26 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates a broad-spectrum SPF50+ sunscreen on 42 adults with Atopic Dermatitis, measuring skin tolerance and barrier function.
The study includes several visits as follow :
- Visit 1: Inclusion (Day 1)
- Visit 2: Intermediate Visit (Day 8)
- Visit 3: End of Study (Day 22)
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Test group | – | Other: Sunscreen RV4620A RP2552Adult intended to use Sunscreen RV4620A RP2552 product |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Subjects will be recruited from the investigation centre's panel. They will be selected on the basis of inclusion and non inclusion criteria specific to the study and on their ability to comply with the constraints required by the protocol. They will be definitely included in the study after a specific interview and a clinical examination.
Key inclusion criteria (21 listed)
- Phototype: from I to VI.
- Sun Exposure: Adults anticipating at least 6 exposures of 2 hours each during the study.
- Swimming Sessions: Subjects planning at least 4 swimming sessions, with a minimum of 50% intending to swim twice in the sea and twice in a pool.
- Sensitive Skin: At least 50% of subjects report having sensitive skin.
- Health Insurance: Must be registered with health social security or health insurance.
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sunscreen RV4620A RP2552Dermo-cosmetic product, Broadspectrum Sunscreen RV4620A RP2552, very high protection product Instructions for product use given to the subjects: Apply before and during sun exposure, at least twice daily. During sun exposure, applications must be renewed as often as necessary, in particular after swimming, perspiring, towelling, in order to ensure a good protection. On days of bad weather, apply the product in the morning and at the beginning of the afternoon. | Other | Test group |
Primary outcome
Global tolerance assessment by the investigator
Time frame: At the end of the study, after Last Patient Out, (after Day 22)
Global tolerance of the product is assessed on the "tolerance population" which includes all the subjects who applied investigational product at least once. This assessment allows for attribution of one of the 5 levels : excellent, very good, good, moderate, bad.
5 secondary outcomes
Evaluation Cosmetic Acceptability of the Sunscreen RV4620A - RP2552
Time frame: Visit 3 (Day 22)
Evaluation of Irritative Factors with Sunscreen RV4620A - RP2552
Time frame: Visit 1 (Day 1, before investigational product application) and Visit 3 (Day 22)
Evaluation of Transepidermal Water Loss with Sunscreen RV4620A - RP2552
Time frame: Visit 1 (Day 1, before investigational product application) and Visit 3 (Day 22)
Assessment of Skin pH with Sunscreen RV4620A - RP2552
Time frame: Visit 1 (Day 1, before investigational product application) and Visit 3 (Day 22)
Assessment of the Lipidic Index Evolution with Sunscreen RV4620A - RP2552
Time frame: Visit 1 (Day 1, before investigational product application) and Visit 3 (Day 22)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Sep 2025.
Related trials for Atopic Dermatitis (AD)
RecruitingPhase 3
Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis
Atopic Dermatitis, Atopic Dermatitis (AD)
RecruitingPhase 1
A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis (AD)
Not yet recruitingPhase 1
A Study of NOR-101 in Healthy Adults and Adults With Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis (AD)
RecruitingPhase 2
PRA-216 Atopic Dermatitis Safety and Efficacy Study
Atopic Dermatitis (AD)
RecruitingPhase 2
Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis (AD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Atopic Dermatitis (AD) and SCORAD Index(15-25), run by Pierre Fabre Dermo Cosmetique at 1 site in Mauritius.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 21 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Mauritius. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Global tolerance assessment by the investigator (time frame: At the end of the study, after Last Patient Out, (after Day 22)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Sep 2025.